Omacetaxine mepesuccinate for the treatment of leukemia

Author： Kim Theo Daniel   Frick Mareike   le Coutre Philipp  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.15, 2011-10, pp. : 2381-2392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

By Nazha Aziz   Kantarjian Hagop   Cortes Jorge   Quintás-Cardama Alfonso  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 14, 2013-10 ,pp. : 1977-1986

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetic evaluation of decitabine for the treatment of leukemia

By Bryan Jeffrey   Kantarjian Hagop   Garcia-Manero Guillermo   Jabbour Elias  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 5, 2011-05 ,pp. : 661-672

Informa Healthcare

Access to resources Recommend Favorite

Bendamustine for treatment of chronic lymphocytic leukemia

By Chang Julie Elizabeth   Kahl Brad Steven  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1495-1505

Informa Healthcare

Access to resources Recommend Favorite

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Strategies for the Treatment of Acute Promyelocytic Leukemia

By Frankfurt Olga   Tallman Martin S.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 37-50

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite